Previous Close | 1.2200 |
Open | 1.2200 |
Bid | 1.1100 x N/A |
Ask | 1.2100 x N/A |
Day's Range | 1.2200 - 1.2200 |
52 Week Range | 0.9700 - 2.9400 |
Volume | |
Avg. Volume | 0 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for O1P.MU
By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT Fourth Quarter Preliminary Results Following our initiation of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share, management provided an update on fourth quarter revenues which are expected to be $12.1 million, a 21% sequential increase over third quarter levels and a 323% year over year increase. We
Insiders who bought US$1.6m worth of RVL Pharmaceuticals plc ( NASDAQ:RVLP ) stock in the last year have seen some of...
-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- -- Approximately 4,300 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the fourth quarter 2022, a 23% increase from the end of the third quarter 2022 -- BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: